skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8121

Antidepressant therapy with milnacipran and venlafaxine

Review

(1993) Views  (408) Full article downloads

Author: Lucilla Mansuy

Published Date August 2010 Volume 2010:6(Supplement 1) Pages 17 - 22
DOI: http://dx.doi.org/10.2147/NDT.S11776

Lucilla Mansuy
Pierre Fabre Médicament, Toulouse, France

Abstract: Specific serotonin norepinephrine reuptake inhibitors (SNRIs) have been described as “better tolerated tricyclic antidepressants” or as “boosted” selective serotonin reuptake inhibitors (SSRIs). Venlafaxine has become a therapeutic reference treatment for major depression. Although less widely studied, indirect comparisons with another SNRI, milnacipran, suggest an equivalent efficacy. This paper discusses these indirect comparisons and the recently published first double-blind, head-to-head comparison. Venlafaxine has potency at serotonin transporters which is about 30-fold greater than that at norepinephrine transporters while milnacipran has a similar potency at each transporter. Thus, at low doses, venlafaxine acts essentially as a SSRI, with significant noradrenergic activity only occurring at higher doses. To overcome the problem of the differing profile of venlafaxine at increasing doses, the first head-to-head study compared the therapeutic effects and tolerability of the two antidepressants when flexibly titrated to the high dose of 200 mg/day. The study showed that the two SNRIs have similar efficacy and safety profiles. Both drugs produced about 42% remissions at the end of the 20-week study. The most frequent adverse events in both groups were nausea, dizziness, headache, and sweating. Certain specific differences in tolerability are discussed.

Keywords: milnacipran, venlafaxine, antidepressant efficacy, tolerability, dose-titration




 

Other articles by Dr Mike Briley

Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study
Choking risk among psychiatric inpatients
Editorial Foreword - Milnacipran: recent findings in depression
Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
Improvement of the noradrenergic symptom cluster following treatment with milnacipran
Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
Milnacipran: a unique antidepressant?
Milnacipran: recent findings in depression
Noradrenergic symptom cluster in depression
Psychiatric diagnoses in patients with burning mouth syndrome and atypical odontalgia referred from psychiatric to dental facilities
Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series
Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran
The importance of norepinephrine in depression
The increasing burden of depression
The noradrenergic symptom cluster: clinical expression and neuropharmacology
Treatment of patients with comorbid depression and diabetes with metformin and milnacipran